title: Pancreatic metastases: a multicentric study of 22 patients.
abstract: OBJECTIVE
  To evaluate the diagnosis, treatment and outcome of patients with pancreatic metastases.
  
  
  METHODS
  We retrospectively reviewed the records of patients with pancreatic metastasis managed in the Paris area between 1990 and 2000.
  
  
  RESULTS
  The series analyzed included 22 patients, 10 men and 12 women, mean age 61 years (range: 35-76). The primary tumors were renal-cell carcinoma (N=10), colorectal cancer (N=4), lung cancer (N=4), breast cancer (N=2), cutaneous melanoma (N=1) and ileal carcinoid (N=1). The mean interval between primary treatment and presentation was 73.5 months (range: 2-151). Diagnosis was established because of clinical symptoms (N=15) or during surveillance (N=7). Computed tomography (N=19) and endoscopic ultrasound (EUS) (N=18) mainly showed solitary and hypodense/or hypoechoic masses. Histological diagnosis was obtained before surgery by EUS-guided fine needle aspiration (N=6), ultrasound-guided biopsy (N=3) or duodenoscopy (N=3). Among 10 patients with primary renal-cell carcinoma, 7 were treated by surgery. Median global survival was 33 months. Median survival was 61 months in the event of surgical treatment and 20 months in the other patients (ns). Mean survival depended on the type of primary tumor, 61 months for renal-cell carcinoma and 33 for colorectal cancer (P=0.06).
  
  
  CONCLUSIONS
  Most pancreatic metastases develop from renal-cell carcinoma and can occur several years after nephrectomy. Histological diagnosis is often obtained before surgery. Surgical resection must be discussed as it can allow long-term survival.
authors.affiliation: Service d'Hépato-Gastroentérologie et d'Oncologie Digestive, Hôpital Ambroise Paré, Boulogne Billancourt.
authors.forename: Abdallah
authors.initials: A
authors.lastname: Moussa
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Mitry
authors.forename: Pascal
authors.initials: P
authors.lastname: Hammel
authors.forename: Alain
authors.initials: A
authors.lastname: Sauvanet
authors.forename: Tania
authors.initials: T
authors.lastname: Nassif
authors.forename: Laurent
authors.initials: L
authors.lastname: Palazzo
authors.forename: David
authors.initials: D
authors.lastname: Malka
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Delchier
authors.forename: Catherine
authors.initials: C
authors.lastname: Buffet
authors.forename: Stanislas
authors.initials: S
authors.lastname: Chaussade
authors.forename: Thomas
authors.initials: T
authors.lastname: Aparicio
authors.forename: Philippe
authors.initials: P
authors.lastname: Lasser
authors.forename: Philippe
authors.initials: P
authors.lastname: Rougier
authors.forename: Gilles
authors.initials: G
authors.lastname: Lesur
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000556:secondary* / Q000601:surgery*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000556:secondary* / Q000601:surgery*; D010297:Paris; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors